Phoenix Biotech Acquisition Stock Cash Per Share
| PBAXDelisted Stock | USD 10.90 0.00 0.00% |
Phoenix Biotech Acquisition fundamentals help investors to digest information that contributes to Phoenix Biotech's financial success or failures. It also enables traders to predict the movement of Phoenix Stock. The fundamental analysis module provides a way to measure Phoenix Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phoenix Biotech stock.
Phoenix |
Phoenix Biotech Acquisition Company Cash Per Share Analysis
Phoenix Biotech's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Phoenix Biotech Cash Per Share | 0.02 X |
Most of Phoenix Biotech's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phoenix Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Phoenix Biotech Acquisition has a Cash Per Share of 0.02 times. This is 99.94% lower than that of the Capital Markets sector and significantly higher than that of the Financials industry. The cash per share for all United States stocks is 99.6% higher than that of the company.
Phoenix Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phoenix Biotech's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phoenix Biotech could also be used in its relative valuation, which is a method of valuing Phoenix Biotech by comparing valuation metrics of similar companies.Phoenix Biotech is currently under evaluation in cash per share category among its peers.
Phoenix Fundamentals
| Return On Asset | -0.0255 | |||
| Current Valuation | 36.13 M | |||
| Shares Outstanding | 6.23 M | |||
| Shares Owned By Insiders | 95.20 % | |||
| Shares Owned By Institutions | 14.92 % | |||
| Number Of Shares Shorted | 757 | |||
| Price To Book | 123.73 X | |||
| EBITDA | (5.74 M) | |||
| Net Income | (2.52 M) | |||
| Cash And Equivalents | 553.77 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 650 K | |||
| Current Ratio | 13.88 X | |||
| Book Value Per Share | (2.20) X | |||
| Cash Flow From Operations | (1.71 M) | |||
| Short Ratio | 0.79 X | |||
| Earnings Per Share | (0.35) X | |||
| Beta | 0.044 | |||
| Market Capitalization | 34.85 M | |||
| Total Asset | 42.37 M | |||
| Retained Earnings | (10.76 M) | |||
| Working Capital | 11.62 M | |||
| Z Score | 31.7 | |||
| Net Asset | 42.37 M |
About Phoenix Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phoenix Biotech Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phoenix Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phoenix Biotech Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |